Imeik Technology Development Co.,Ltd. Stock price

Equities

300896

CNE100004868

Medical Equipment, Supplies & Distribution

End-of-day quote Shenzhen S.E. 07:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
338.4 CNY -0.48% Intraday chart for Imeik Technology Development Co.,Ltd. +1.05% +14.97%
Sales 2024 * 3.92B 542M Sales 2025 * 5.24B 724M Capitalization 72.82B 10.08B
Net income 2024 * 2.47B 342M Net income 2025 * 3.26B 451M EV / Sales 2024 * 17.5 x
Net cash position 2024 * 4.2B 582M Net cash position 2025 * 6.43B 890M EV / Sales 2025 * 12.7 x
P/E ratio 2024 *
29.7 x
P/E ratio 2025 *
22.5 x
Employees 910
Yield 2024 *
1.21%
Yield 2025 *
1.57%
Free-Float 35.05%
More Fundamentals * Assessed data
Dynamic Chart
Imeik Technology Development's Profit Rises 47% on Higher Revenue MT
Imeik Technology Development Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Tranche Update on Imeik Technology Development Co.,Ltd.'s Equity Buyback Plan announced on June 12, 2023. CI
Imeik Technology Development Co.,Ltd.'s Equity Buyback announced on June 12, 2023, has closed with 1,165,874 shares, representing 0.54% for CNY 399.69 million. CI
QL Biopharmaceutical announced that it has received CNY 200 million in funding from BlueRun Investment Consulting Co., Ltd., Imeik Technology Development Co.,Ltd., China-US Green Fund Management Co., Ltd., Shenzhen Jiayuan Capital Management Co., Ltd., Chengdu Science and Technology Innovation Investment Group Co., Ltd., Shanghai Jincheng Equity Investment Fund Management Co., Ltd. and other investors CI
Imeik Technology Wins Exclusive Rights to Distribute Jeisys’ Aesthetic Equipment in China MT
Imeik Technology Development Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Tranche Update on Imeik Technology Development Co.,Ltd.'s Equity Buyback Plan announced on June 12, 2023. CI
Imeik Technology Development Co.,Ltd. Approves Cash Distribution for the First Half of 2023, Payable on 23 October 2023 CI
Imeik Technology Development Co.,Ltd. Proposes Distribution for the First Half of 2023 CI
Imeik Technology Development's Profit Jumps 65.7% in H1 MT
Imeik Technology Development Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Tranche Update on Imeik Technology Development Co.,Ltd.'s Equity Buyback Plan announced on June 12, 2023. CI
Imeik Technology Development Co.,Ltd. announces an Equity Buyback for CNY 400 million worth of its shares. CI
Imeik Technology Development Co.,Ltd. authorizes a Buyback Plan. CI
More news
1 day-0.48%
1 week+1.05%
Current month+3.49%
1 month+6.87%
3 months+12.12%
6 months-13.29%
Current year+14.97%
More quotes
1 week
332.50
Extreme 332.5
345.82
1 month
314.69
Extreme 314.69
358.00
Current year
267.58
Extreme 267.58
358.00
1 year
263.21
Extreme 263.21
595.08
3 years
263.21
Extreme 263.21
844.44
5 years
172.78
Extreme 172.7778
844.44
10 years
172.78
Extreme 172.7778
844.44
More quotes
Managers TitleAgeSince
Chief Executive Officer 50 09-12-31
Director of Finance/CFO 46 21-10-31
44 -
Members of the board TitleAgeSince
Chairman 68 22-11-16
Director/Board Member 59 21-07-11
Director/Board Member 59 16-10-31
More insiders
Date Price Change Volume
24-03-28 338.4 -0.48% 1,791,626
24-03-27 340 +0.75% 2,628,779
24-03-26 337.5 +1.07% 1,543,812
24-03-25 334 -1.37% 1,571,312
24-03-22 338.6 +1.11% 2,341,311

End-of-day quote Shenzhen S.E., March 27, 2024

More quotes
Imeik Technology Development Co Ltd is a China-based company mainly engaged in the research and development, production and sales of biomedical materials. The Company focuses on the development and transformation of biomedical materials, and is committed to the development of biomedicine such as recombinant proteins and peptides. The Company has realized the industrialization of injection-type sodium hyaluronate series products and polydioxanone facial implants, and has established a product technology transformation platform for biomedical materials such as medical chitosan and polylactic acid. The Company's self-developed products are mainly aimed at the repair of fold skin on the face and neck. The clinical applications of its products cover medical cosmetology, surgical repair, and treatment of metabolic diseases. The Company mainly conducts its businesses in the China market.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
19
Last Close Price
338.4 CNY
Average target price
454.4 CNY
Spread / Average Target
+34.29%
Consensus
  1. Stock
  2. Equities
  3. Stock Imeik Technology Development Co.,Ltd. - Shenzhen S.E.